key: cord-0933929-r9dtmasg
authors: Barandalla, Ignacio; Alvarez, Carmen; Barreiro, Pablo; de Mendoza, Carmen; González-Crespo, Rubén; Soriano, Vicente
title: Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
date: 2021-09-15
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.09.022
sha: 23fd88ac11906e1a085fda13c2cbd78e74760437
doc_id: 933929
cord_uid: r9dtmasg

Background The advent of SARS-CoV-2 vaccines has been associated with a significant decline in COVID-19 hospitalizations and deaths. However, little is known about the benefits experienced by different population groups and/or using distinct vaccines. Methods We analyzed the Spanish public registry for associations between calendar vaccination scale up and incidence of COVID-19 hospitalizations by age, gender and vaccine modality. The study period extended from January 2020 to June 2021. Results A total of 363,960 COVID-19 hospitalizations were recorded in Spain during the study period, with three peaks in March 2020, November 2020 and January 2021. The incidence of COVID-19 hospitalizations per 100,000 population exponentially increased with age, on average 71.5% for each decade older. Overall individuals older than 60 years-old accounted for 65% of all COVID-19 hospitalizations. Speedy vaccination rollout since the end of 2020 with prioritization of the elderly groups resulted in a rapid drop of COVID-19 hospitalizations since February 2021. The benefit was already noticed 3-4 weeks after the first dose, regardless vaccine modality. Conclusions COVID-19 hospitalizations increased exponentially with age in all three peaks of SARS-CoV-2 infection in Spain. Early massive vaccination of people above 60-years precluded a fourth wave of COVID-19 hospitalizations during the spring of 2021.

The recent global spreading of SARS-CoV-2 infection in humans is unprecedented in medicine (Morens et al., 2020) . At the end of June 2021, over 180 million cases had been reported worldwide with nearly 4 million deaths. In Spain, these figures were of nearly 4 million confirmed cases and over 80,000 deaths. In the absence of effective antiviral agents against SARS-CoV-2, the advent of vaccines has been eagerly awaited. The first vaccines achieved emergency approval in December 2020 after proving significant protection for development of severe COVID-19 in clinical trials [Polack et al. 2020; Baden et al., 2021) .

Vaccine rollout began immediately with prioritization of the most vulnerable populations, including the elderly and health care workers.

Several surges of COVID-19 have been recognized in different countries, largely depending on mitigation interventions mandated at country level. In Spain, three large waves have been well characterized so far, with peaks of COVID-19 hospitalizations and deaths in March 2020 Pollan et al., 2020; Moreno-Torres et al., 2021) , November 2020 (Soriano et al., 2021a) and January 2021 (Soriano et al., 2021b) .

Speedy vaccination rollout since the end of 2020 in Spain with prioritization of the elderly groups and health care workers resulted in a rapid drop of COVID-19 hospitalizations since February 2021. Herein, we exam in detail the impact of vaccination on nationwide COVID-19

hospitalizations.

We examined all COVID-19 hospitalizations in Spain from February 2020 to June 2021 using the national public registry, which is freely available at the website of the Health Ministry (CNE, 2021) . During this 17-month period, age, gender and calendar of all hospitalized patients were analyzed. Likewise, we examined all information available for vaccines administered by calendar and modality recorded at the Health Ministry website (MS, 2021) .

Consecutive decades were considered for age ranges in our analyses. Calendar periods were grouped by weeks. Vaccine modalities were four, two using mRNA marketed by Pfizer (Polack et al., 2020) and Moderna (Baden et al, 2021) , one using a chimp adenovirus as vector marketed by AstraZeneca (Voysey et al., 2021) and another from Janssen that uses a replication-deficient human adenovirus vector (Sadoff et al., 2021) . All but the latest are given as two doses.

Crude data were drawn in Excel files as absolute numbers and percentages. Patients were grouped by range age using consecutive decades. The incidence of COVID-19 hospitalization for each age group was expressed as number of hospitalizations per 100,000 population in that age range. Data on national population and age and sex distribution were recorded from the Spanish Statistical database (SNIS, 2021) . Calendar COVID-19 hospitalizations were grouped by weeks reported on the following Monday. Exponential regression was adjusted using the least square method.

In order to figure out the impact of vaccines, we estimated the expected hospitalizations during 2021, extrapolating data from the second wave, when hospital beds were always available (in contrast with the first wave) and vaccines still were not marketed. The estimations were made for distinct age groups. As shown in the supplementary Figure 1 and Table 1, proportions of each age group as part of the total from the second wave were very stable and reliable, and accordingly we chose as 'reference window' the period from the week reported on October 12 th to the week reported on January 4 th . Those proportions are considered as the canonical hospitalization incidence rates for each age group.

When the effect of vaccines on COVID-19 hospitalizations began to be recognized, estimates for hospitalization incidence for each age group were assessed weekly applying the canonical proportions. As controls, we considered the age groups that had been less vaccinated, and curves of "hospitalizations in the absence of vaccines" were estimated applying the canonical proportions for matched ages. In this way, the real COVID-19 hospitalization incidence was compared with estimated hospitalizations in the absence of vaccines.

The following three reference age groups were used:

 For weeks reported from 11-Jan-2021 to 08-Feb-2021, the reference age group was 50-59, since that age group had a very low vaccination coverage during that timeframe (<2%).

 For weeks reported from 15-Feb-2021 to 12-Apr-2021, the reference age group was 70-79, since after the first vaccinations for this age group at nursing homes, the rest of the population within this age range living at their homes had to wait for vaccination until full completion of the 80-89 age group. Less than 5% of this age group had received one dose during this timeframe.

 For weeks reported from 19-Apr-2021 to 21-Jun-2021, the reference age group was the combination of 30-39 and 40-49 years-old. These two age groups were combined to have greater statistical significance, because the hospitalization numbers were low. The vaccination coverage with 1 dose for these age groups reached 15% by mid-June. By then, the 80-89 age group had reached 100%, the 70-79 had reached 98%, the 60-69 group had reached 92% and the 50-59 group had reached 76%. Therefore, a 15% vaccine coverage was an acceptable threshold to be considered as low impacted by vaccination. o Every week, the number of "people with at least 1 dose" and "people with full vaccination" in all age groups should match with the total number of vaccines administered in Spain.

o The number of "people with at least 1 dose" and "people with full vaccination" every week should be equal or larger than the previous week for each age group.

o The number of "people with full vaccination" in a certain week should not be larger than the number of "people with at least 1 dose" from 3 weeks before using Moderna/Pfizer.  The age group 70-79 received initially a large number of doses (roughly 100,000) explained by easy access to elderly living at skill nursing homes. Thereafter, the rhythm of vaccination slowed down because elderly living separately at their homes had to be contacted individually by their general practitioners.

The official population in Spain by mid-2020 was of 47.5 million people, being women 51%. years-old. Overall, more men than women were hospitalized with COVID-19, but below 40years of age women were more frequently hospitalized than men. Figure 1 shows the COVID-19 hospitalization incidence for each age range. Regardless gender, older age was by far the major determinant of COVID-19 hospitalization. The adjusted risk increased exponentially on average 71.5% for each decade older above 20 years-old. SARS-CoV-2 vaccination in Spain begun at the end of 2020. Two main groups were prioritized, including the elderly living at nursing homes and health care workers. Figure 4 records the scaling up of vaccination by age groups. Vaccines Pfizer and Moderna were the only available at that time. Two doses 3-4 weeks apart were recommended. Since March 2021, AstraZeneca was also prescribed, giving two doses 10-12 weeks apart. The Janssen vaccine was only prescribed since May 2021.

The administration of at least one dose of SARS-CoV-2 vaccines had been recorded for 55% of the population in Spain up to June 21 st 2021. The complete vaccination schedule with two doses (for all but Janssen) had been recorded for 34% of the population. The distribution of vaccines administered was as follows: Pfizer 67%, Moderna 9%, AstraZeneca 20% and Janssen 4%. We did not recognize any differential impact of distinct vaccines on COVID-19 hospitalization rates, considering age ranges or gender (data not shown). The strong inverse relationship between vaccination rollout and COVID-19 hospitalizations was noticed initially in the oldest groups that became vaccinated earlier. When declines in COVID-19 hospitalizations at distinct age groups were examined alongside vaccinations in the same age group, a significant correlation was found with a 3-4-week delay on average after the first dose (Figure 6) . Indeed, the second dose only added a slight benefit on hospitalizations.

Since the end of 2019 SARS-CoV-2 infection has spread worldwide transforming human lives and societies. The first wave of COVID-19 erupted abruptly in Europe on March 2020, being Spain one of the epicenters (Dur-e-Ahmad et al., 2020; Liu et al., 2021) ). High mortality rates among the elderly at skill nursing homes and collapse of hospitals occurred within a few weeks . Home confinement and lockdown of most activities were implemented over six weeks. In our analysis of nationwide COVID-19 hospitalizations the surge on March 2020 must be interpreted as an underestimation of the real number of severe cases, since access to diagnostic tests was poor and a large proportion of older people did not die at hospitals but at their skill nursing homes (Candel et al., 2021) .

Relaxation of social distancing measures during the summer was followed by a new surge in October 2020, alongside partial return to work and reopening of schools and universities.

Finally, a third wave of COVID-19 hospitalizations was noticed after Christmas time, most likely reflecting family gatherings (Guallar et al., 2020; Thompson et al., 2021) .

It is noteworthy that older age was the major determinant of hospitalization. Above 20 years-old, for each decade older there was an exponential increased risk of hospitalization of 71.5%, more clearly manifested during the second and third waves. On average, individuals above 80 years-old represented 27% of hospital admissions. In contrast, persons younger than 40-years-old and children represented only 9% of hospitalizations. Of note, the incidence of hospitalizations was greater in younger women than men; although male had a higher hospitalization rate above 40-years-old. This finding most likely was due to the fact that almost all infected pregnant women were recommended to stay at hospital for close monitoring until resolution (Cruz et al., 2021) .

The introduction of vaccines since the end of 2020 had a significant impact on COVID-19

hospitalizations. The prioritization of vaccination of the elderly at skill nursing homes and of health care workers began to be noticed in February 2021. Subsequently, the steady vaccination of the oldest persons living at their homes and essential workers consolidated the decline in COVID-19 hospitalizations. Accordingly, new COVID-19 hospitalizations were diminished and mostly occurred in younger patients that had not been vaccinated.

People above 80 years-old were no longer the most frequent hospitalized since the last week of March 2021. Since mid-May neither those above 70-years-old. Since early June 2021, COVID-19 hospitalizations were low, being mostly represented by the residual population younger than 50-years-old not vaccinated yet.

It is noteworthy that overall protection from COVID-19 hospitalizations rose to near 91% for vaccinees, in line with data from registrational vaccine trials regarding severe COVID-19 (Polack et al., 2020; Baden et al., 2021; MS, 2021) . Furthermore, the clinical protection from COVID-19 hospitalization was seen after the first vaccine shot in all age groups, including the oldest ones in which immune responses hypothetically could be impaired. Our results are in line with preliminary evidence from registrational clinical trials (Connors et al., 2021) and challenge the recognition of a low humoral response after the first shot, suggesting that protection derived from cellular immune responses might be more important than previously thought (Stankov et al., 2021) . On the other hand, our results are in support of recent evidence suggesting that people that already had SARS-CoV-2 infection may safely skip the second vaccine shot (Wang et al., 2021) . This information is important because could help to stretch scarce vaccine supplies in some countries.

We could not find differences in vaccine protection attributed to distinct vaccines, although for Janssen the numbers were low and follow-up short to draw definitive conclusions. By far, Pfizer had been the most frequently prescribed COVID-19 vaccine up to June 2021 in Spain.

Some authors have argued that massive SARS-CoV-2 vaccination in the midst of a pandemic might be a wrong intervention, favoring the selection of vaccine-escape mutants. We could not find any evidence in favor of such threat. Although vaccine breakthrough infections due to new variants have been well demonstrated, they often are clinically mild and generally do not require hospitalization (Hacisuleyman et al., 2021) . In Spain, up to June 30 th , more transmissible SARS-CoV-2 variants alpha to delta have consecutively replaced the original SARS-CoV-2 strain (Alcoba-Florez et al., 2021; Campoy et al., 2021) . However, vaccine protection remains clinically evident based on the low rate of COVID-19 hospitalizations. Our data are in agreement with most studies that have examined the protective efficacy of current vaccines over the new variants. All uniformly have highlighted that changes in neutralization activity does not seem to translate into complete vaccine failure with symptomatic illness (Wang et al., 2021; Kustin et al., Nat Med 2021) .

We should acknowledge several caveats and potential limitations of our study, especially with respect to conclude that the lack of a fourth wave of COVID-19 hospitalizations in Spain largely was the result of the prior massive vaccine roll out of the most vulnerable populations by Easter. At least another three reasons could contribute to explain this benefit. First, the growing and already large subset of people infected and with immunity by then. Second, the acquisition of knowledge on social distance and other protective measures that were uniformly implemented. Third, the evolving and changing criteria for hospitalization of infected persons, with prioritization of disease management at home when possible. We will address each point separately.

First, the population already infected and with natural immunity by Easter was low. Since we had an unexpected surge of cases (fifth wave) on July 2021 driven by the highly transmissible SARS-CoV-2 delta variant (Seppäla et al., 2021) , it is clear that herd immunity had not been achieved in Spain. Moreover, we were able to estimate what proportion of protection during the fourth wave resulted from vaccination. By far the vast majority of hospitalizations in elderly people during the fourth and the largest fifth wave mostly occurred in the remaining subset of non-vaccinated individuals.

Second, the hard lockdown was only forced during the first wave in March-April 2020. Social distancing measures were implemented during subsequent months with intermittent intensity but anymore forcing home confinement. Recommendations included wearing indoor face masks, gathering restrictions, curfew, etc. Therefore, the low plateau in new diagnoses of severe cases (those requiring hospitalization) after Easter (corresponding to the fourth wave) largely resulted from the beneficial impact of a massive coverage of vaccination for the most vulnerable oldest population.

Third, the criteria for admission into hospital wards during the pandemic has evolved as result of improved knowledge that has allowed to refrain from hospitalization people with no acute severe signs/symptoms and lack of worsening predictors (older age, obesity, male gender, etc.). However, hospital room capability has increased since the first wave, when many severely ill patients did not have the chance to be hospitalized because the health system became overwhelmed. Altogether, our interpretation is that hospitalization criteria did not affect much our results.

In summary, nationwide records of COVID-19 hospitalizations in Spain support that massive vaccination of people above 60-years-old precluded a fourth wave of COVID-19 hospitalizations after Easter time. The protective effect on COVID-19 hospitalizations was noticed shortly after the first dose of the current marketed vaccines.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

Monitoring the rise of the SARS-CoV-2 lineage B.1.1.7 in Tenerife (Spain) since mid

COVE Study Group. Efficacy and safety of the mRNA-1273

SARS-CoV-2 vaccine

First importations of SARS-CoV-2 P

2 variants from Brazil to Spain and early community transmission

The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study

SARS-CoV-2 vaccines: much accomplished, much to learn

Pregnancy outcomes and SARS-CoV-2 infection: The Spanish Obstetric Emergency Group Study

Transmission dynamics model of coronavirus COVID-19 for the outbreak in most affected countries of the world

Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity

Vaccine breakthrough infections with SARS-CoV-2 variants

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

A new SEAIRD pandemic prediction model with clinical and epidemiological data analysis on COVID-19 outbreak

Emerging pandemic diseases: how we got to COVID-19

C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway

Why such excess of mortality for COVID-19 in Spain?

Main differences between the first and second waves of COVID-19 in Madrid, Spain

Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination

SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection